Curious about today's AI digest?ai-tldr.dev

Daily Digest

BriefMarket · mixedMedium impact
Esc

SELLAS Stock More Than Doubles After Phase 3 Trial Win

SELLAS Life Sciences (company press release)2 min read6 sources

Why is SELLAS stock up today?

SELLAS Life Sciences (SLS) stock more than doubled on Tuesday, from a $7.47 close to above $17, after its Phase 3 leukemia vaccine trial met its survival goal, cutting death risk by 41%.

Key numbers

Reduction in risk of death41%Hazard ratio 0.59 vs best available treatment
Median survival, GPS24.0 monthsvs 14.7 months on standard care
Statistical significance (p-value)0.035Usual cutoff is 0.05
SLS share price$17.83+139% vs $7.47 prior close at 9:50 a.m. ET
Market value (per MarketBeat)$3.68BIntraday; shares traded as high as $27.05

What happened

SELLAS Life Sciences (SLS) stock more than doubled on Tuesday, from a $7.47 close to above $17, after its Phase 3 leukemia vaccine trial met its survival goal, cutting death risk by 41%. The trial tested a cancer vaccine, galinpepimut-S (GPS), in 126 people with a blood cancer (AML) who were in remission but could not have a stem cell transplant. People on the vaccine lived a median of 24 months, versus 14.7 months on standard care. SELLAS aims to file for FDA approval in the first half of 2027.

Why it matters

SELLAS Life Sciences is a small drug developer, and a successful Phase 3 trial is the step that decides whether it can ask regulators to approve a medicine. Few treatments exist for AML patients who cannot have a transplant, so living about nine months longer on average would be meaningful if it holds up. The figures are early results from the company and have not been peer reviewed, and the test result (p=0.035) cleared the usual 0.05 bar by a modest margin.

Who this affects

Marketmixed
Medium impact
Biotech traders saw wild swings, with temporary trading halts.
Companybullish
High impact
SELLAS shareholders gain sharply; an FDA filing is targeted for 2027.
Competitorsmixed
Low impact
Other AML drug makers could face a new maintenance option.
Industrybullish
Medium impact
Cancer vaccines get fresh evidence of a survival benefit.

SELLAS Life Sciences vs Syndax, Kura Oncology

SELLAS Life SciencesSLS$3.68BMore than 2x—
Syndax PharmaceuticalsSNDX———
Kura OncologyKURA———

As of 2026-11-17

How we got here

  1. Maxim Group analyst keeps Buy rating and $30 price target ahead of trial data.

  2. SELLAS reports REGAL trial met its survival goal; shares surge in premarket trading.

  3. Trading is temporarily halted several times as the stock swings sharply.

What to watch

  • FDA meeting on a faster filing path, then a drug application for GPSH1 2027
  • Full secondary results at a medical conference and in a peer-reviewed journalNot yet scheduled
  • Early data from SELLAS's second AML drug, tambiciclib (SLS009)Q4 2026

Educational content only. Not investment advice.

More briefsAll briefs →